Vertex Pharmaceuticals (VRTX) Capital Leases (2011 - 2025)

Vertex Pharmaceuticals' Capital Leases history runs 15 years deep, the most recent figure standing at $111.4 million for Q1 2025.

• On a quarterly basis, Capital Leases fell 69.18% year-over-year to $111.4 million in Q1 2025; TTM through Mar 2025 was $111.4 million, a 69.18% decrease from a year earlier, with the FY2024 full-year figure at $112.8 million, down 70.01% from the prior year.
• Capital Leases slipped to $111.4 million in Q1 2025 per VRTX's latest filing, from $112.8 million in the prior quarter.
• Across five years, Capital Leases topped out at $530.3 million in Q1 2021 and bottomed at $111.4 million in Q1 2025.
• The 5-year median for Capital Leases is $417.6 million (2023), against an average of $386.1 million.
• Across the five-year window, Capital Leases rose 0.55% in 2021 and sank 70.79% in 2024, its largest moves.
• Year by year, Capital Leases stood at $509.8 million in 2021, then fell by 15.5% to $430.8 million in 2022, then decreased by 12.7% to $376.1 million in 2023, then sank by 70.01% to $112.8 million in 2024, then slipped by 1.24% to $111.4 million in 2025.
• Per Business Quant, the three latest VRTX Capital Leases figures stand at $111.4 million (Q1 2025), $112.8 million (Q4 2024), and $114.0 million (Q3 2024).